Italia markets open in 3 hours 49 minutes

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
9,53+0,12 (+1,28%)
Alla chiusura: 04:00PM EST
9,26 -0,27 (-2,83%)
Dopo ore: 07:10PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente9,41
Aperto9,46
Denaro8,60 x 900
Lettera9,26 x 1000
Min-Max giorno9,31 - 9,85
Intervallo di 52 settimane1,45 - 10,67
Volume1.789.881
Media Volume346.793
Capitalizzazione471,89M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-2,01
Prossima data utili01 mar 2023 - 06 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A9,00
  • GlobeNewswire

    Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

    FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023 at 10:10 a.m.

  • GlobeNewswire

    Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

    FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET

  • GlobeNewswire

    Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

    Plans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases Expects to initiate proof of concept trials in CML and obesity and to report top-line data from DUET, the first trial assessing THR-β agonist as monotherapy and in combination with FXR agonist for NASH Cash and cash equivalents, together with the $112 million from proceeds raised in December 2022, expected to provide runway into 2026 FOSTER CITY, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmac